# US 2025/0082729 A1 · Biomarkers and treatment methods for traumatic brain injury-associated impairments

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082729 A1
- Document ID: US20250082729A1
- Status: Published application
- Kind: A1
- Application number: 18/957,221
- Filed: 2024-11-22
- Published: 2025-03-13
- Earliest claimed: 2018-06-29
- Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Applicants: University of Pittsburgh- of the Commonwealth System of Higher Education
- Inventors: Amy Kathleen Wagner
- Web page: https://patentgrep.com/patent/US20250082729A1

## CPC

- A61K 38/2046: {IL-7}
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- C07K 16/241: {Tumor Necrosis Factors}
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G01N 2333/70578: NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
- G01N 2800/28: Neurological disorders
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure relates to methods, compositions, and kits for treating traumatic brain injury (TBI) and TBI-associated impairments in a subject. The methods include administering to the subject an interleukin-7 (IL-7) or IL-7 agonist, a tumor necrosis factor alpha (TNFα) inhibitor, or both. The present disclosure also relates to methods of using biomarkers for identifying a subject that is likely to respond to a treatment for TBI-associated impairments, and monitoring the subject's response to such treatment.

## Claims

### Claim 1

A method of treating a traumatic brain injury (TBI)-associated impairment, in a subject that has sustained a TBI, comprising administering to the subject a TNFα inhibitor, wherein the TNFα inhibitor is selected from the group comprising etanercept, etanercept-szzs, adalimumab, adalimumab-adbm, adalimumab-adaz, adalimumab-atto, and golimumab.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method further comprises administering to the subject interleukin-7 (IL-7) or an IL-7 agonist.

### Claim 3 (depends on 2)

The method of claim 2, wherein the IL-7 is a recombinant IL-7.

### Claim 4 (depends on 1)

The method of claim 1, wherein the method comprises an increase in a Glasgow Outcome Scale (GOS) score of the subject,
wherein the GOS score is assessed at least three distinct time points post-TBI,
wherein a first time point assessment occurs within 6 months post-TBI,
wherein a second time point assessment occurs within 12 months post-TBI,
wherein a third time point assessment occurs within 24 months post-TBI, and
wherein the GOS score increases from the first time point assessment to the second or third time point assessment.

### Claim 5 (depends on 4)

The method of claim 4, wherein the method comprises a reduction in a Disability Rating Scale (DRS) score of the subject,
wherein the DRS score is assessed at least three distinct time points post-TBI,
wherein a first time point assessment occurs within 6 months post-TBI,
wherein a second time point assessment occurs within 12 months post-TBI,
wherein a third time point assessment occurs within 24 months post-TBI, and
wherein the DRS score reduces from the first time point assessment to the second or third time point assessment.

### Claim 6 (depends on 1)

The method of claim 1, wherein the method comprises an increase in a serum IgM level in the subject,
wherein the serum IgM level is assessed at least three distinct time points,
wherein a first time point assessment occurs prior to treatment,
wherein a second time point assessment occurs within 1 month post-TBI,
wherein a third time point assessment occurs within 24 months post-TBI, and
wherein the serum IgM level increases from the first time point assessment to the second or third time point assessment.

### Claim 7 (depends on 1)

The method of claim 1, wherein the method comprises an increase in a serum IgM:IgG ratio in the subject,
wherein the serum IgM:IgG ratio is assessed at least three distinct time points,
wherein a first time point assessment occurs prior to treatment,
wherein a second time point assessment occurs within 1 month post-TBI,
wherein a third time point assessment occurs within 24 months post-TBI, and
wherein the serum IgM:IgG ratio increases from the first time point assessment to the second or third time point assessment.

### Claim 8 (depends on 1)

The method of claim 1, wherein the TBI-associated impairment is selected from the group consisting of cognitive deficits, psychological deficits, somatic symptoms, emotional symptoms, behavioral dysfunctions, physical dysfunctions, and neuroendocrine dysfunction.

### Claim 9 (depends on 1)

The method of claim 1, wherein the TNFα inhibitor is administered to the subject at the acute stage, at the post-acute stage and/or at the chronic stage of the TBI.

### Claim 10

A method for treating a TBI-associated impairment in a subject that has sustained a TBI, comprising:
(a) determining a level of Neutrophil-Lymphocyte Ratio (NLR) and a level of IL-7 in at least two samples obtained from the subject;
(b) comparing the level of NLR to a reference level of NLR and the level of IL-7 to a reference level of IL-7,
wherein the reference levels of NLR and IL-7 are predetermined levels,
wherein the predetermined levels of NLR and IL-7 are from (i) a healthy individual or a population of healthy individuals free of the TBI-associated impairment or (ii) the same subject collected at an earlier time point,
wherein the reference level of IL-7 is about 25 μg/ml, and
wherein the reference level of NLR is about 10;
(c) assigning trajectory group memberships to the subject by assessing the IL-7 and NLR levels of the subject in relation to group-based trajectory analyses derived from a population with TBI,
wherein if the level of IL-7 is lower than the reference level of the IL-7 the subject is assigned a low IL-7 trajectory group membership,
wherein if the level of IL-7 is higher than the reference level of the IL-7 the subject is assigned a high IL-7 trajectory group membership,
wherein if the level of NLR is lower than the reference level of NLR the subject is assigned a low NLR trajectory group membership,
wherein if the level of NLR is higher than the reference level of NLR the subject is assigned a high NLR trajectory group membership; and
(c-i) treating the subject with IL-7 if the subject is assigned a low IL-7 trajectory group membership and a low NLR trajectory group membership,
(c-ii) treating the subject with IL-7 and etanercept if the subject is assigned a low IL-7 trajectory group membership and a high NLR trajectory group membership;
or (c-iii) treating the subject with etanercept if the subject is assigned a high IL-7 trajectory group membership and a high NLR trajectory group membership.

### Claim 11 (depends on 10)

The method of claim 10, wherein the dose of IL-7 is higher in (c-ii) than in (c-i).
